NCT04978181 is a clinical trial of Alteplase Injection in Acute Stroke, sponsored by Assiut University.

Who is sponsoring NCT04978181?

NCT04978181 is sponsored by Assiut University.

What drugs are being tested in NCT04978181?

Interventions in NCT04978181: Alteplase Injection.

What condition does NCT04978181 study?

NCT04978181 studies Acute Stroke.

Is NCT04978181 still recruiting?

NCT04978181 is currently status unknown. Last updated 27 July 2021.

Last reviewed 2021-07-27 · How we verify

NCT04978181

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Prevalence and Associated Factors of Early Deterioration After Successful Recanalization in Acute Ischemic Stroke

Status unknown Last updated 27 July 2021

What this trial tests

trial testing Alteplase Injection in Acute Stroke in 30 participants. Status unknown.

Timeline

1 August 2021

Primary endpoint
30 July 2022

1 August 2022

Quick facts

Lead sponsor	Assiut University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	30
Start date	1 August 2021
Primary completion	30 July 2022
Estimated completion	1 August 2022

Drugs / interventions tested

Alteplase Injection — full drug profile →

Conditions studied

Acute Stroke — all drugs for Acute Stroke →

Sponsor

Assiut University

Who can join

Adults 18 to 90, any sex, with Acute Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

stroke is a leading cause of morbidity and mortality worldwide. More than half (54.5%) of the 56.9 million deaths worldwide in 2106 were due to the top 10 causes. Ischemic heart disease and stroke are the world's biggest killers, accounting for a combined 15.2 million deaths in 2106. These diseases have remained the leading causes of death globally in the last 15 years. Recent clinical trials have shown that endo-vascular thrombectomy is an effective and safe recanalization modality for acute ischemic stroke patients . Meta-analysis results show that endovascular treatment is associated with a high ratio of successful recanalization rate and a low rate of symptomatic hemorrhage . Approximately 2.2-37.5% of patients with acute ischemic stroke might encounter early neurological deterioration (END). Definition of END: An increase in NIHSS ≥4 or an increase in Ia of NIHSS ≥1 within 72 h after recanalization treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Acute Stroke

Currently open trials in the same condition.

NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
NCT07295366 — Early Administration of PCSK9 Inhibitors After Thrombectomy for Atherosclerotic Acute Ischemic Stroke: A Randomized Cont · Phase 4 · recruiting
NCT07355881 — mSOAR and Early Mortality in Acute Stroke · recruiting
NCT07301372 — Evaluation Study of Early Administration of Evolocumab After Thrombolysis in Patients With Atherosclerotic Acute Ischemi · Phase 4 · recruiting
NCT07167550 — The Study of Efficacy and Safety of Dimephosphon® in Acute Ischemic Stroke · Phase 3 · recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04978181 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 27 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04978181.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing